DexCom (DXCM) Stock: Buy, Sell, or Hold?
DXCM - DexCom, Inc.
$83.03
-1.48 (-1.75%)
▼
5d:
-7.45%
30d:
-8.56%
90d:
+10.34%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 29, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 4, 2026 at $87.90 · last confirmed Sep 9, 2026
Strength: 8.0/10
Get Alerted When DXCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: DXCM shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: DXCM shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$127.93
Based on 10.7% avg growth
INTRINSIC VALUE TODAY
$79.43
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DXCM is currently trading at $83.03, which is considered oversold relative to its 30-day fair value range of $85.42 to $91.02. The stock's valuation (Forward PE: 26.6) is in line with its historical norms (24.8). At these levels, the market is pricing in 2.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DXCM is in a strong uptrend. The price is currently testing key support at $82.29. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DXCM scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $94.12 (+13.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DXCM is in a strong uptrend. The price is currently testing key support at $82.29. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DXCM scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $94.12 (+13.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$85.42 -
$91.02
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.7%
Protect Your Profits
Holding DXCM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (24/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($94.12)
- NEUTRAL: Market pricing in 2.4% annual earnings growth - fairly valued
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$85.42 -
$91.02
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$82.29
Resistance Level
$92.34
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
26.58
Wall Street Target
$94.12
(+13.4%)
Revenue Growth (YoY)
13.1%
Earnings Growth (YoY)
43.6%
Profit Margin
20.1%
Valuation Premium vs History
+2.4% premium
PE vs Historical
26.6 vs 24.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.4%
(market-implied from PE analysis)
1-Year Target
$85.02
(+2%)
2-Year Target
$87.06
(+5%)
3-Year Target
$89.15
(+7%)
3-Yr Target (if PE normalizes)
(PE: 27→25)
PE COMPRESSION
$83.19
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 26.6, Growth: 17.3%)
$134.16
(+62%)
Base:
(SPY PE: 20.2, Growth: 17.3%)
$101.82
(+23%)
Bear:
(PE: 17.1, Growth: 17.3%)
$86.55
(+4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (33x PE), but valuation improves significantly next year (27x PE) as earnings recover.
Trailing PE: 33.14 | Current EPS (TTM): $2.55
Bull Case
$113.89
(+37%)
Analyst growth 22.5%, PE expands to 36.5
Base Case
$103.54
(+25%)
Market implied 22.5%, PE stable at 33.1
Bear Case
$57.47
(-31%)
Severe decline -20.0%, PE contracts to 28.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 5:33 PM ET
Data refreshes hourly during market hours. Next update: 6:33 PM
Data refreshes hourly during market hours. Next update: 6:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DXCM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Jon Brown
SELL
1700 shares
2026-04-15
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 41 HOLD |
|
ZBH
Zimmer Biomet Holdings I… |
HOLD
29 analysts |
$108 | 50 HOLD |
Advanced DXCM Option Strategies
Professional options setups generated by AI based on today's DXCM price and gamma walls.
